LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

20.77 -3.17

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

20.4

Maxim

20.96

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+62.44% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-329M 2.6B
Deschiderea anterioară	23.94
Închiderea anterioară	20.77

Sentimentul știrilor

By Acuity

67%

33%

289 / 344 Clasament în Healthcare

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 iun. 2026, 23:38 UTC

Achiziții, Fuziuni, Preluări

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 iun. 2026, 22:08 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 iun. 2026, 21:55 UTC

Achiziții, Fuziuni, Preluări

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 iun. 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 iun. 2026, 21:22 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 iun. 2026, 20:46 UTC

Achiziții, Fuziuni, Preluări

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 iun. 2026, 20:22 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares $11 Special Div

1 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 iun. 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 iun. 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 iun. 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 iun. 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 iun. 2026, 18:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 iun. 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 iun. 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 iun. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 iun. 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 iun. 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 17:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

62.44% sus

Prognoză pe 12 luni

Medie 34.86 USD 62.44%

Maxim 36 USD

Minim 34 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

289 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.